Abstract The coronavirus disease 2019 (COVID-19) pandemic is an exceptional public
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …

The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises.
Several vaccine approaches and repurposed drugs are currently under evaluation for safety …

SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …

As the number of people infected with the newly identified 2019 novel coronavirus (SARS-
CoV2) is continuously increasing every day, development of potential therapeutic platforms …

Abstract Coronavirus disease 2019 (COVID-19) is expanding rapidly, which made it as one
of top priorities for scientists to develop novel treatment strategies. Researchers are racing to …

The pandemic of Coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) continues to be a global health crisis …

Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infections often cause only
mild disease that may evoke relatively low Ab titers compared with patients admitted to …

Antibodies are a principal determinant of immunity for most RNA viruses and have promise
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …

The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly
develop therapeutics and prophylactics against SARS-CoV-2. The SARS-CoV-2 spike …

A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated
respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the …